CXCR4 and neoplasm: A recent phase I trial in women with advanced HER-2 negative metastatic breast cancer investigated a combination regimen of balixafortide (a peptidic CXCR4 antagonist) and eribulin and demonstrated favorable safety and tolerability as well as promising anti-tumor activity (32).